{"id":1582,"date":"2023-08-08T09:07:02","date_gmt":"2023-08-08T09:07:02","guid":{"rendered":"https:\/\/healthynewsusa.com\/?p=1582"},"modified":"2023-08-08T09:07:05","modified_gmt":"2023-08-08T09:07:05","slug":"seeking-medicare-coverage-for-weight-loss-drugs-pharma-giant-courts-black-influencers","status":"publish","type":"post","link":"https:\/\/healthynewsusa.com\/?p=1582","title":{"rendered":"Seeking Medicare Coverage for Weight Loss Drugs, Pharma Giant Courts Black Influencers"},"content":{"rendered":"
\n

Pharmaceutical giant Novo Nordisk has turned to influential Black Americans in pursuit of what would be a lucrative victory: having Medicare cover a new class of weight loss drugs, including the company\u2019s highly sought Wegovy, which can cost patients more than $1,000 a month.<\/p>\n

During a conference of the Congressional Black Caucus Foundation last fall \u2014 a jampacked gathering<\/a> featuring prominent Black lawmakers and President Joe Biden \u2014 Novo Nordisk sponsored a panel discussion on obesity for which it selected the moderator and panelists, company spokesperson Nicole Ferreira said. The foundation is a nonprofit affiliated with the Congressional Black Caucus, a powerful group of lawmakers on Capitol Hill.<\/p>\n

Former CNN political commentator Roland Martin moderated. Black health experts who support Medicare coverage of drugs used to treat obesity served on the panel. They included Fatima Cody Stanford, an associate professor of medicine at Harvard Medical School. Stanford is a specialist in obesity who has received consulting fees from Novo Nordisk.<\/p>\n

During the panel discussion, Stanford told the audience that obesity \u201cis a real disease that people struggle with,\u201d she recounted in an interview with KFF Health News. \u201cWe\u2019ve denied people care for obesity when we haven\u2019t for other chronic diseases.\u201d<\/p>\n

Novo Nordisk, the leading maker of so-called obesity drugs, followed up on the September panel by sponsoring a streaming show in March hosted by Martin, during which guests advocated for Medicare to cover drugs for weight loss. Ferreira said the company suggested experts for the segment, but she did not name them.<\/p>\n

Those activities are part of a broader Novo Nordisk campaign to shift the public narrative about obesity. They open a new window on drugmakers\u2019 efforts to influence consumers and public policy.<\/p>\n

Novo Nordisk is trying to reverse a 20-year-old ban on coverage of drugs used for weight loss under Medicare, the federal health insurance program primarily for people 65 and older. Congress excluded such medications<\/a> when it established Medicare\u2019s Part D prescription drug benefit in 2003. The ban effectively deprives drugmakers of millions of potential customers.<\/p>\n

\n

\n\t\t
\n\t\t\tEmail Sign-Up\t\t<\/a>
\n\t<\/h4>\n

\n\t\tSubscribe to KFF Health News’ free Morning Briefing.\t<\/p>\n<\/div>\n

Expanding the Patient Pool<\/strong><\/p>\n

Medicare coverage would put obesity drugs within reach of many people who could not otherwise afford them. It could have a multiplier effect because private insurers often follow Medicare\u2019s lead.<\/p>\n

It would be a financial boon to Novo Nordisk and other drugmakers, including Eli Lilly, which is seeking FDA approval for a weight loss drug.<\/p>\n

Adding to the cost, and the potential upside for the industry: To keep weight off, patients may have to take the drugs indefinitely.<\/p>\n

Wegovy\u2019s list price is about $1,350 for roughly a month\u2019s supply. Eli Lilly\u2019s Mounjaro, a drug for people with Type 2 diabetes that doctors prescribe off-label for obesity, is priced at about $1,023 for roughly a month\u2019s supply.<\/p>\n

Wegovy is FDA-approved for weight loss in adults who have a body mass index of 30 or greater \u2014 the definition of adult obesity, according to the Centers for Disease Control and Prevention \u2014 or a BMI of at least 27 plus at least one weight-related medical condition, such as hypertension. It\u2019s also approved for patients as young as 12 who are deemed obese.<\/p>\n

In a statement, Novo Nordisk spokesperson Allison Schneider said, \u201cWe advocate for patients and policies that support access to all obesity treatments, including coverage for anti-obesity medications in Medicare Part D.\u201d<\/p>\n

The company supports the Treat and Reduce Obesity Act<\/a>, legislation introduced in 2013 that would overturn the Medicare coverage ban. In July, a bipartisan group of lawmakers in the House and Senate reintroduced the bill \u2014 something lawmakers have done repeatedly over the decade.<\/p>\n

Drug companies have long used a variety of strategies to advance corporate interests, such as funding so-called patient advocacy groups focused on specific diseases and airing direct-to-consumer ads that spur patients to ask their doctors about brand-name drugs.<\/p>\n

Novo Nordisk is the biggest corporate donor to the Obesity Action Coalition, which says its mission is \u201cto elevate and empower those affected by obesity.\u201d<\/p>\n

Novo Nordisk contributes more than $500,000 annually<\/a> to the group, according to its website. The group\u2019s legislative objectives include reversing Medicare\u2019s coverage ban on weight loss drugs.<\/p>\n

The Obesity Action Coalition \u201cis not influenced in any way by our vast array of supporters,\u201d said Kendall Griffey, a spokesperson for the group.<\/p>\n

Novo Nordisk has advertised Wegovy<\/a>, which the FDA approved for weight loss in 2021, and Ozempic<\/a>, which is approved for diabetes and prescribed off-label to treat obesity.<\/p>\n

Like many large corporations, Novo Nordisk has contributed thousands of dollars annually to nonprofits tied to different groups of lawmakers while seeking support in Congress<\/a> for its causes.<\/p>\n

In 2021, Novo Nordisk gave between $100,000 and $399,999<\/a> to the Congressional Black Caucus Foundation and between $25,000 and $49,999<\/a> to the Asian Pacific American Institute for Congressional Studies, according to each nonprofit\u2019s annual report.<\/p>\n

The latter nonprofit, known as APAICS, is affiliated with the Congressional Asian Pacific American Caucus. APAICS lists Novo Nordisk as a partner on webpages for events in March and May where panel discussions touched on the treatment of obesity.<\/p>\n

The Congressional Hispanic Caucus Institute also lists Novo Nordisk as a donor but doesn\u2019t state how much the company contributed.<\/p>\n

The Congressional Black Caucus, Congressional Hispanic Caucus, and Congressional Asian Pacific American Caucus back a bill <\/a>on health disparities that in 2022 was revised to scrap Medicare\u2019s prohibition<\/a> on covering prescriptions for weight loss.<\/p>\n

The Congressional Black Caucus Foundation, the Congressional Hispanic Caucus Institute, and the Asian Pacific American Institute for Congressional Studies did not respond to questions for this article. Novo Nordisk declined to say how much it contributed to the Congressional Black Caucus Foundation\u2019s 2022 legislative conference and whether it sponsored the panel to influence Congressional Black Caucus members\u2019 positions; it similarly declined to specify its most recent annual contribution to the Congressional Hispanic Caucus Institute and its financial contributions for various APAICS events this year. \u201cWe support multiple organizations to help educate on and highlight issues important to their communities,\u201d company spokesperson Natalia Salomao said of Novo Nordisk\u2019s relationship with the nonprofits.<\/p>\n

High-Profile Promoters<\/strong><\/p>\n

Martin\u2019s streaming daily news show in March featured an hourlong segment<\/a> \u201cpowered by Novo Nordisk\u201d on obesity among Black Americans. Ferreira, of Novo Nordisk, said Martin and Novo Nordisk \u201cagreed that a segment on his show was a good opportunity to reach his audience to help further inform them about obesity as a chronic disease and the importance of good nutrition and health care.\u201d<\/p>\n

\n

\n<\/p>\n